Amicus Therapeutics, Inc. (FOLD) |
|
11.09 0.18 (1.65%)
|
03-31 16:00 |
|
Open: |
11.03 |
Pre. Close: |
10.91 |
|
High:
|
11.21 |
Low:
|
11 |
|
Volume:
|
2,108,405 |
Market Cap:
|
3,135(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:18:49 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 14.8 One year: 16.16 |
| Support: |
Support1: 10.8 Support2: 8.98 |
| Resistance: |
Resistance1: 12.67 Resistance2: 13.84 |
| Pivot: |
11.25  |
| Moving Average: |
MA(5): 11.1 MA(20): 11.4
MA(100): 12.08 MA(250): 10.75 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 25.1 %D(3): 24.7 |
| RSI: |
RSI(14): 38.7 |
| 52-week: |
High: 13.84 Low: 5.9 |
| Average Vol(K): |
3-Month: 2,225 (K) 10-Days: 2,062 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FOLD ] has closed above bottom band by 28.1%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.3 - 11.37 |
11.37 - 11.43 |
|
Low:
|
10.66 - 10.72 |
10.72 - 10.79 |
|
Close:
|
10.81 - 10.92 |
10.92 - 11.02 |
|
Company Description |
|
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. |
Headline News |
Sat, 01 Apr 2023
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at ... - Defense World
Tue, 28 Mar 2023
Bank of America Securities Analyst Gives Amicus Therapeutics a ... - Best Stocks
Mon, 27 Mar 2023
Bank of America Raises Amicus Therapeutics (NASDAQ:FOLD ... - MarketBeat
Mon, 27 Mar 2023
Amicus Therapeutics (FOLD) Announces European Commission ... - StreetInsider.com
Thu, 23 Mar 2023
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet? - Simply Wall St
Fri, 10 Mar 2023
Amicus Therapeutics is Now Oversold (FOLD) - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
283 (M) |
| Shares Float |
204 (M) |
|
% Held by Insiders
|
0.8 (%) |
|
% Held by Institutions
|
105.9 (%) |
|
Shares Short
|
18,090 (K) |
|
Shares Short P.Month
|
19,650 (K) |
Stock Financials |
|
EPS
|
-0.81 |
|
EPS Est Next Qtl
|
-0.29 |
|
EPS Est This Year
|
-1.33 |
|
EPS Est Next Year
|
-1.02 |
|
Book Value (p.s.)
|
0.43 |
|
Profit Margin (%)
|
-71.9 |
|
Operating Margin (%)
|
-62.1 |
|
Return on Assets (ttm)
|
-15.7 |
|
Return on Equity (ttm)
|
-110 |
|
Qtrly Rev. Growth
|
7.1 |
|
Gross Profit (p.s.)
|
1.02 |
|
Sales Per Share
|
1.16 |
|
EBITDA (p.s.)
|
-0.71 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-167 (M) |
|
Levered Free Cash Flow
|
-94 (M) |
Stock Valuations |
|
PE Ratio
|
-13.87 |
|
PEG Ratio
|
0.2 |
|
Price to Book value
|
25.2 |
|
Price to Sales
|
9.52 |
|
Price to Cash Flow
|
-18.83 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
